Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint
Crinetics Pharmaceuticals saw its stock rise by 10.6% following the submission of a Marketing Authorization Application for its drug PALSONIFY in Brazil. This move expands the drug's regulatory presence beyond its existing US approval and European opinion, signaling Crinetics' strategy to build a global franchise for acromegaly treatment. While the Brazil filing is a positive step, the article notes that investors should remain focused on the US launch execution and potential risks related to prescription uptake and payer access.
Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
Aberdeen Group plc significantly increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 98.4% in Q4, acquiring an additional 334,584 shares to hold a total of 674,533 shares valued at approximately $31.4 million. Despite this institutional buying, Crinetics Pharmaceuticals has seen insider selling, with the CFO and a director offloading shares. The company has a "Moderate Buy" analyst consensus with an average price target of $76.63, although its financial metrics include a negative P/E ratio and a market cap of $3.90 billion.
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ
Crinetics Pharmaceuticals Inc. (CRNX) stock is currently trading at $36.26, up 5.81% (+$1.99). The article provides live quotes and charts for CRNX, but notes that there is no analyst rating information or earnings data currently available. It also promotes various trading tools and educational content.
CRNX PE Ratio & Valuation, Is CRNX Overvalued
Crinetics Pharmaceuticals Inc (CRNX) is currently deemed "Undervalued," with its fair price estimated between $65.46 and $109.53, significantly higher than its current $33.67. Despite this, its Price-to-Sales (P/S) ratio of 129.59 is substantially above the competitor average, raising concerns about its sustainability given the robust revenue growth is yet to be fully specified. The article provides various valuation metrics as of March 30, 2026, to support these analyses.
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
The article highlights Indivior, Liquidia, and Crinetics as top Quant pharma picks. It also mentions Merck's acquisition of Terns for $6.7 billion, indicating significant activity and investment in the pharmaceutical sector.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts
Crinetics Pharmaceuticals (NASDAQ:CRNX) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $76.63. Despite beating recent earnings estimates, the company remains unprofitable, and its shares are trading below key moving averages at $33.67. Insider selling has been observed, while institutional investors hold a significant portion of the stock.
Crinetics Pharma Director Stock Sale - March 2026 Transaction Details - News and Statistics
A director at Crinetics Pharmaceuticals, Rogerio Vivaldi Coelho, sold 5,000 shares of company stock for an approximate value of $181,000. This transaction, conducted under a pre-established trading plan, reduced his direct holdings by about 23.5% to 16,300 shares. Crinetics Pharmaceuticals is a clinical-stage biotechnology company focused on oral therapeutics for rare endocrine diseases, with a reported market capitalization of approximately $3.97 billion.
Is Crinetics (CRNX) Using Brazil’s PALSONIFY Filing To Cement Its Global Endocrine Leadership?
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application for PALSONIFY in Brazil, aiming to expand its global reach for the acromegaly treatment. While this filing adds potential international markets, the company's near-term focus remains on the US launch uptake of PALSONIFY, alongside the ongoing risk of high cash burn. The article also notes recent leadership changes and highlights that analysts hold varying revenue expectations for Crinetics' future.
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
A director at Crinetics Pharmaceuticals sold 5,000 shares worth approximately $180,761 on March 12, 2026, as part of a pre-scheduled Rule 10b5-1 trading plan. This sale represented 23.47% of his direct holdings and is his only disclosed open-market sale for the company. The article suggests this is a strategic liquidity move rather than a reflection of diminishing confidence, especially as Crinetics is poised for growth with its lead drug launch and robust financial position.
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) from a "hold" to a "sell" rating. This comes despite Crinetics beating quarterly EPS and revenue estimates, though the company remains deeply unprofitable. Shares fell 7.3% to $33.67, and insiders have recently sold over $2.29 million worth of shares.
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
The article highlights that Indivior, Liquidia, and Crinetics are top-ranked pharmaceutical companies according to quantitative analysis. It also reports on Merck's acquisition of Terns for $6.7 billion, indicating significant M&A activity in the pharma sector. This acquisition suggests a strategic move by Merck to expand its portfolio.
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
A director at Crinetics Pharmaceuticals sold 5,000 shares for approximately $180,761, representing 23.47% of his direct holdings, under a pre-scheduled Rule 10b5-1 trading plan. The article emphasizes that this sale is likely a strategic liquidity move rather than a signal of waning confidence, as the company is well-positioned for growth with new product launches and a strong cash reserve. Investors should focus on the company's expanding pipeline and early commercialization successes, such as $7.7 million in revenue for 2025, rather than this insider transaction.
Crinetics Pharmaceuticals Announces Submission of Marketing
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application (MAA) in Brazil for PALSONIFY™ (paltusotine) to treat acromegaly in adults, following its FDA approval in the US. This submission is supported by extensive clinical data, including two positive Phase 3 trials. PALSONIFY is a once-daily, oral therapy that has shown efficacy in maintaining IGF-1 levels and controlling symptoms in acromegaly patients.
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify (Paltusotine) in Acromegaly
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application (MAA) to Brazil's ANVISA for PALSONIFY™ (paltusotine), an oral therapy for acromegaly in adults. This submission is supported by comprehensive clinical data, including two positive Phase 3 trials. PALSONIFY is already approved in the US and has received a positive opinion from the CHMP in Europe for the same indication.
Vanguard disaggregates holdings; Crinetics (CRNX) parent reports 0 shares
The Vanguard Group has filed an amended Schedule 13G/A for Crinetics Pharmaceuticals (CRNX) reporting 0 shares beneficially owned. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately. This disaggregation means The Vanguard Group parent entity no longer reports beneficial ownership of these subsidiary-held securities.
Brazil gets filing for once-daily acromegaly pill backed by 18 trials
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application (MAA) for PALSONIFY (paltusotine) in Brazil for the treatment of acromegaly in adults. This submission is supported by data from 18 clinical trials, including two Phase 3 studies that met all primary and secondary endpoints. PALSONIFY is already approved in the US and has received a positive CHMP opinion in Europe, indicating the company's global commercialization efforts.
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application (MAA) to Brazil’s National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), an oral treatment for acromegaly in adults. This submission follows the drug's approval in the U.S. and a positive opinion in Europe, supported by two successful Phase 3 trials. Once-daily PALSONIFY is designed to manage IGF-1 levels and symptoms in acromegaly patients.
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B
This article identifies Indivior, Liquidia, and Crinetics as leading pharmaceutical companies according to a quantitative analysis. The news coincides with Merck's significant acquisition of Terns for $6.7 billion, indicating notable activity within the pharmaceutical market. The article will likely detail why these companies are topping the quant list.
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA)
Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, bolstering its oncology pipeline. Meanwhile, Indivior Pharmaceuticals, Liquidia, and Crinetics Pharmaceuticals lead the list of top U.S.-listed pharmaceutical stocks based on Seeking Alpha Quant Ratings. These ratings consider valuation, growth, momentum, profitability, and EPS revisions for their rankings.
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript
Crinetics Pharmaceuticals Inc. (FRA:6Z4) held its Q2 2025 earnings call, where it highlighted the anticipated FDA approval of Paltusine in September and its potential to be a transformative launch. The company reported a strong financial position with $1.2 billion in cash, sufficient to fund operations until 2029, despite increased R&D and SG&A expenses. Key points included pipeline progress for carcinoid syndrome and congenital adrenal hyperplasia, and significant engagement with healthcare professionals.
Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026
Crinetics Pharmaceuticals, Inc. announced the resignation of Jeff Knight, Chief Development and Operating Officer, effective on or about April 10, 2026. Knight is leaving to pursue another opportunity, and his departure is not due to any disagreements with the company's operations, policies, or practices. His responsibilities will be reassign
Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026)
Crinetics Pharmaceuticals, Inc. filed a Form 8-K announcing the resignation of Jeff Knight, Chief Development and Operating Officer, effective April 10, 2026. His departure is for another opportunity and not due to any disagreements with the company. His responsibilities will be reassigned within the existing executive leadership team, and the company has not indicated plans for an immediate replacement.
Crinetics' Jeff Knight to Resign as Chief Development and Operating Officer
Jeff Knight, Chief Development and Operating Officer of Crinetics (CRNX), is set to resign from his position on or about April 10, 2026. His departure is for another opportunity and is not related to any disagreements with the company. His managerial responsibilities will be reassigned to other executive leadership team members.
Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026
Crinetics Pharmaceuticals announced that Jeff Knight, its Chief Development and Operating Officer, will resign effective April 10, 2026, to pursue another opportunity. The company clarified that his resignation is not due to any disagreements regarding operations, policies, or practices. All of Mr. Knight's managerial responsibilities and direct reports will be reassigned to other members of the executive leadership team internally.
Crinetics Pharmaceuticals chief development and operating officer to resign
Crinetics Pharmaceuticals announced the resignation of its Chief Development and Operating Officer, Jeff Knight, effective April 10, 2026, due to "another opportunity." The company clarified the resignation is not due to any disagreements and highlighted its strong financial position with a $3.72 billion market cap and robust liquidity. This news follows the company's strong Q4 2025 financial results and a revised price target from Citizens based on promising early adoption rates for the drug Palsonify.
JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
JPMorgan Chase & Co. significantly increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) during the third quarter, purchasing 926,765 additional shares to bring its total to 1,258,722 shares, valued at approximately $52.4 million. This represents a 279.2% increase and makes JPMorgan Chase & Co. a 1.33% owner of the company. Other institutional investors also boosted their holdings, with institutional investors collectively owning about 98.51% of Crinetics stock, while company insiders sold shares worth about $2.29 million during the same period.
CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of Crinetics Pharmaceuticals Inc (CRNX), detailing its revenue breakdown, profitability margins, and a comparison with competitors. It highlights CRNX's gross margin of 82.54% but notes negative operating and net margins, alongside a negative Return on Equity. The company's market capitalization is $3.72 billion, and it is benchmarked against industry leaders like INDV and GPCR.
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes
Crinetics Pharmaceuticals' Chief Operating Officer, Jeff E. Knight, sold 9,911 shares of common stock on March 16, 2026, to cover tax withholding obligations related to vested restricted stock units. The sales were executed at volume-weighted average prices of $37.11 and $37.77 per share under a Rule 10b5-1 trading plan. Following these transactions, Knight directly holds 112,018 shares of Crinetics common stock.
Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) COO Sells 9,911 Shares of Stock
Crinetics Pharmaceuticals (NASDAQ:CRNX) COO Jeff Knight sold 9,911 shares of the company's stock for over $370,000, reducing his ownership by 8.13%. Following the insider sale, CRNX shares dropped approximately 4.9% to $36.05, trading below its 50- and 200-day moving averages. Despite the sale and stock dip, analysts maintain a "Moderate Buy" rating with an average target price of $74.78.
Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Stephen Betz Sells 10,612 Shares
Crinetics Pharmaceuticals (NASDAQ:CRNX) insider Stephen Betz sold 10,612 shares of the company's stock for approximately $396,570 on March 16. This transaction reduced his stake by 7.18%, bringing his total holdings to 137,101 shares valued at about $5.12 million. The stock subsequently traded down 4.9% to $36.05, impacting its year-to-date performance.
Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax
Crinetics Pharmaceuticals' Chief Scientific Officer, Stephen F. Betz, sold 10,612 shares of common stock on March 16, 2026. These transactions, executed in two blocks at volume-weighted average prices of $37.11 and $37.77 per share, were explicitly for covering tax withholding obligations associated with vested restricted stock units. Following these sales, which were conducted under a pre-arranged Rule 10b5-1 trading plan, Betz directly holds 137,101 shares of Crinetics common stock.
Crinetics (CRNX) CEO discloses tax-related share sales under 10b5-1 plan
Crinetics Pharmaceuticals' President & CEO, Richard Scott Struthers, sold 21,981 shares of CRNX common stock on March 16, 2026. These sales, executed under a Rule 10b5-1 trading plan, were conducted by a broker to cover tax withholding obligations associated with the vesting of restricted stock units from previous years. After these transactions, Struthers directly holds 404,778 shares, with additional indirect holdings through family trusts and his spouse.
CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise
An insider at Crinetics Pharmaceuticals (CRNX) has filed a Form 144, indicating proposed sales of 15,000 shares via option exercise and settlement of 9,756 Restricted Stock Units. The filing also discloses three completed 10b5-1 sales, each for 5,000 shares, that occurred on January 2, 2026, February 2, 2026, and March 2, 2026, with total proceeds of over $680,000. These transactions are described as compensation-related liquidity events and pre-arranged trading.
Jim Cramer on Crinetics: “That’s a better spec than Aquestive”
Jim Cramer commented on Crinetics, favoring it as a speculative investment over Aquestive. This brief statement suggests his preference for CRNX in the biotech sector for investors looking for higher risk, potentially higher reward opportunities.
Jim Cramer on Crinetics: “That’s a better spec than Aquestive”
This article features Jim Cramer's commentary comparing Crinetics (CRNX) to Aquestive (AQST). He declared Crinetics a "better spec" than Aquestive, indicating a preference for CRNX as a speculative investment.
[144] Crinetics Pharmaceuticals, Inc. SEC Filing
This article details a Form 144 SEC filing by Crinetics Pharmaceuticals, Inc. (CRNX) concerning the proposed sale of securities. The filing indicates the sale of 25,113 shares of common stock, with an aggregate market value of $941,486, acquired through restricted stock unit vesting. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker for the sale, which is dated March 16, 2026, on the Nasdaq.
[144] Crinetics Pharmaceuticals, Inc. SEC Filing
This article details a Form 144 SEC filing by Crinetics Pharmaceuticals, Inc. concerning a proposed sale of securities. The filing, dated March 16, 2026, indicates a neutral impact and sentiment. It provides information about the filer, issuer, and the specific securities to be sold, which are common shares acquired through Restricted Stock Unit Vesting.
Crinetics Pharmaceuticals, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Crinetics Pharmaceuticals, Inc. (CRNX) submitted on March 16, 2026. The filing indicates a proposed sale of 45,013 shares of common stock by an unnamed individual, acquired through restricted stock unit vesting, with an aggregate market value of over $1.6 million. The transaction is set to be handled by Morgan Stanley Smith Barney LLC.
First Light Asset Management LLC Acquires 77,380 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
First Light Asset Management LLC increased its stake in Crinetics Pharmaceuticals, Inc. by 9.0% in Q3, purchasing 77,380 shares to hold a total of 941,516 shares valued at $39.2 million. This makes Crinetics Pharmaceuticals its sixth-largest holding. Despite significant institutional investment (98.51%) and a "Moderate Buy" average analyst rating with an average target of $74.78, the company remains unprofitable and insiders have sold shares totaling $703,565 in the last 90 days.
Farallon Capital Management LLC Increases Position in Crinetics Pharmaceuticals, Inc. $CRNX
Farallon Capital Management LLC significantly increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 24.2% during the third quarter, now owning 5,770,098 shares valued at $240,325,000. Other institutional investors also adjusted their holdings. The article also details recent insider sales, the company's financial performance including a negative PE ratio of -7.59 and a consensus "Moderate Buy" rating from analysts with an average target price of $74.78.
Prosight Management LP Buys 30,561 Shares of Crinetics Pharmaceuticals, Inc. $CRNX
Prosight Management LP increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 10.3% in the third quarter, purchasing an additional 30,561 shares to own a total of 328,684 shares valued at $13.7 million. Institutional investors now collectively own about 98.51% of the company. Despite several analysts issuing "Buy" or "Overweight" ratings with an average price target of $74.78, the company continues to report losses, with a recent EPS of ($1.29) and anticipated full-year EPS of -3.73.
Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now?
Crinetics Pharmaceuticals has experienced recent stock price weakness, declining over 21% in the last 30 days and 19.8% year-to-date, despite strong long-term returns. A Discounted Cash Flow (DCF) analysis by Simply Wall St suggests the stock is significantly undervalued by 91.9%, estimating an intrinsic value of $464.66 per share compared to its current price of $37.49, while its Price-to-Book ratio indicates it's trading above industry and peer averages. The article encourages investors to explore valuation further using their proprietary tools and narratives.
Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now?
Crinetics Pharmaceuticals (CRNX) has experienced a recent stock price decline, raising questions about a potential valuation opportunity. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 91.9%, with an intrinsic value of $464.66 per share compared to its current price of $37.49. However, its Price-to-Book (P/B) ratio of 3.96x is higher than the industry and peer averages, indicating it might be more expensive based on some metrics.
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility
Crinetics Pharmaceuticals (CRNX) has experienced recent share price volatility despite strong long-term returns. While one valuation narrative suggests the company is 55.1% undervalued with a fair value of $82.43 per share based on future growth and profitability, a Discounted Cash Flow model indicates an even higher potential value of $464.66 per share. Investors are left to weigh these optimistic valuations against the risks associated with the company being loss-making and the successful uptake of its lead candidate, Paltusotine.
[144] Crinetics Pharmaceuticals, Inc. SEC Filing
This article details a Form 144 SEC filing by Crinetics Pharmaceuticals, Inc. (CRNX) for the proposed sale of 5,000 common shares with an aggregate market value of $184,900. The shares were acquired through an open market purchase on June 8, 2023. The filing indicates the sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility
Crinetics Pharmaceuticals (CRNX) has experienced recent share price volatility despite strong long-term returns, prompting a valuation assessment. While a popular narrative suggests the company is 55.1% undervalued with a fair value of $82.43 per share based on aggressive growth assumptions, a separate discounted cash flow model suggests an even deeper undervaluation at $464.66 per share. Investors are advised to consider these differing valuations alongside risks to make informed decisions.
Systematic review on acromegaly therapies receives journal approval, Crinetics Pharmaceuticals announces
Crinetics Pharmaceuticals announced that its systematic literature review and network meta-analysis of pharmacologic therapies for acromegaly has been accepted for publication in the Journal of Clinical Endocrinology & Metabolism. This achievement signifies growing recognition of Crinetics Pharmaceuticals’ contributions to the endocrinology field. The article highlights the company's efforts to advance research and clinical understanding of acromegaly treatment options.
(CRNX) as a Liquidity Pulse for Institutional Tactics
Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) is showing weak near and mid-term sentiment, posing a challenge to its long-term positive outlook. Stock Traders Daily's AI models have generated three trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Short Risk Hedging Strategy. The deep analysis provides insight into current signals, support, and resistance levels across multiple time horizons, from near-term to long-term.
Crinetics (CRNX) director sells 3,000 shares under 10b5-1 plan
Crinetics Pharmaceuticals director Stephanie Okey sold 3,000 shares of common stock at $39.67 per share on March 3, 2026. This transaction was executed automatically under a Rule 10b5-1 trading plan established on November 19, 2025. Following the sale, Okey now beneficially owns 13,300 shares of Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals, Inc. $CRNX Position Trimmed by GW&K Investment Management LLC
GW&K Investment Management LLC reduced its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 12.4% in the third quarter, selling 120,264 shares and now owning 850,546 shares valued at $35.43 million. Other institutional investors also adjusted their positions, with 98.51% of the stock owned by such entities. The article also details the company's financial performance, recent insider transactions, and updated analyst ratings, reflecting an average "Moderate Buy" rating with a consensus price target of $74.78.
